A knowledgeable and committed CRO partner can make all the difference in a stalled out study, which in the right hands could go on to create a life-changing therapeutic innovation. We discuss what to look for in a “rescue project” partner.
Our team had the opportunity to both attend and present at a number of content-rich sessions during AAPS’ 2018 PharmSci 360 event. These conversations will have a direct impact on our own work moving forward, and we wanted to summarize and share a few of the key takeaways we found most interesting and valuable.
We’ve compiled some key questions to consider when selecting an outsourced partner for bioanalysis, so that you can set your large molecule study up for success from the very start.
What are the benefits of working with an expert team with an open-door policy? In this Q&A, Stuart Logan, BD Manager at BioAgilytix Europe, shares how his colleagues have supported his professional development.
Methods for the detection of drug-induced antibodies have become much more sensitive, but the question remains to be answered: are antibodies at this low concentration level clinically relevant?
With headquarters in the USA and Europe, effective team-wide communication is critical to our success. William Hunter, Director of BD & Global Key Accounts at BioAgilytix Europe, and Todd Lester, BPM at our USA HQ, discuss how they collaborate.
Biomarkers have the potential to inform the drug development process for both large and small molecule drugs. Learn more about our ability to carry out a wide variety of biomarker testing for both types of drugs.
Yang Liu, Associate Director at BioAgilytix Europe and a recent hire to our company, talks with us about his work experience thus far and how he is using his expertise to shape his role.
In this Team Q&A session, Dave Williams, Director, Bioanalytical Operations at BioAgilytix, talks with us about why he made the move from Kansas City to join the BioAgilytix team in 2017, and the ways in which his role has evolved in just one year.
To keep up with the rapidly evolving field of drug development, we must stay on the pulse of bioanalytical innovation. Our latest blog summarizes some of the latest industry articles our team has found noteworthy.
Services
Platforms
